Drug Delivery Devices - G7

  • G7
  • In G7, the revenue in the Drug Delivery Devices market market is projected to reach US$21.93bn in 2024.
  • The revenue is anticipated to exhibit an annual growth rate (CAGR 2024-2029) of 4.79%, which will lead to a market volume of US$27.71bn by 2029.
  • In a global context, the United States is expected to generate the highest revenue, amounting to US$15,010.00m in 2024.
  • In the United States, the drug delivery devices market is increasingly focusing on smart technologies that enhance patient adherence and optimize therapeutic outcomes.
 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

The Drug Delivery Devices Market within the Medical Devices sector in G7 nations is experiencing mild growth, influenced by factors such as technological advancements, increasing prevalence of chronic diseases, and the rising demand for patient-centric treatment solutions.

Customer preferences:
Consumers in G7 nations are increasingly favoring drug delivery devices that offer convenience and personalization, reflecting a shift towards more tailored healthcare solutions. The rise of home healthcare has led to a demand for devices that facilitate self-administration of medications, such as auto-injectors and smart inhalers. Additionally, demographic shifts, including an aging population, are driving interest in user-friendly devices that enhance adherence to treatment regimens, emphasizing the importance of intuitive design in improving patient outcomes.

Trends in the market:
In G7 nations, the drug delivery devices market is experiencing a significant shift towards advanced, user-centric solutions. Consumers are increasingly opting for devices like smart inhalers and auto-injectors, which cater to the growing demand for convenience and personalized healthcare. The aging population is a key driver, as older adults seek intuitive technologies that enhance medication adherence and simplify self-administration. This trend underscores the importance of innovative design, urging industry stakeholders to invest in R&D to meet evolving patient needs and improve health outcomes.

Local special circumstances:
In Japan, the drug delivery devices market is shaped by a rapidly aging population and high healthcare expectations, leading to a demand for precision and reliability in medical technologies. Cultural preferences for quality and safety drive consumers towards established brands known for their innovation. Regulatory frameworks are stringent, necessitating rigorous testing and approval processes, which can delay market entry for new devices. Meanwhile, the integration of technology with traditional healthcare practices fosters a unique environment where smart devices, like connected inhalers, are increasingly embraced for their enhanced user experience.

Underlying macroeconomic factors:
The Drug Delivery Devices Market within the Medical Devices sector is significantly influenced by macroeconomic factors such as demographic shifts, healthcare expenditure, and regulatory dynamics. In countries with aging populations, there is a heightened demand for advanced drug delivery systems that ensure effective medication management. National economic health, reflected in GDP growth and healthcare budgets, directly impacts investment in innovative medical technologies. Furthermore, fiscal policies promoting healthcare R&D foster a conducive environment for market expansion. Global economic trends, such as increasing healthcare costs and a shift towards personalized medicine, further drive the need for efficient and reliable drug delivery solutions, shaping the market landscape.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on medical devices and IVD revenues allocated to the country where the money is spent at manufacturer price levels excluding VAT.

Modeling approach / Market size:

Modeling employs a top-down approach with a bottom-up validation, using financial information of the key players by market. Market sizes are determined by a top-down approach, based on a specific rationale for each market market and allocated to the covered countries according to the global market shares. As a basis for evaluating markets, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, healthcare system, and regulations concerning medical products. Next, we use further relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, healthcare payer system, and regulations concerning medical products. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level.

Overview

  • Revenue
  • Analyst Opinion
  • Global Comparison
  • Methodology
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Ayana Mizuno
Ayana Mizuno
Junior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)